Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Immune Cell Profiling and Antibody Responses in Patients With Covid-19 Publisher Pubmed



Rezaei M1 ; Mahmoudi S2 ; Mortaz E3 ; Marjani M3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Virology Research Center, National Research Institute of Tuberculosis and Lung diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Pediatric Infectious Disease Research Center, Pediatrics Center of Excellence, Children’s Medical Center Hospital, Tehran University of Medical Sciences, Dr. Gharib Street, Keshavarz Boulevard, Tehran, Iran
  3. 3. Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: BMC Infectious Diseases Published:2021


Abstract

Background: Although there are a growing number of studies on evaluating lymphocyte subset counts as prognostic factors for COVID-19 disease severity, the lymphocyte subsets’ analyses of both IgM and IgG responders and non-responders during the periods after onset of symptoms, have not been conducted yet. So, this study aimed to evaluate immune cell profiling of COVID-19 patients with and without antibody responses. Methods: In this cross-sectional study, the levels of peripheral lymphocyte subsets were measured using flow cytometry in 53 patients with positive SARS-CoV-2 RT-PCR, for whom antibody testing of COVID-19 was performed. Results: The white blood cell, neutrophil, and lymphocyte counts consistently decreased in the IgM and IgG non-responder group, while the differences in the median value between the two study groups were found to be statistically significant only in terms of neutrophil counts (P = 0.024 for IgM response and p-value = 0.046 for IgG response, respectively). Moreover, the level of neutrophil-to-lymphocyte ratio was observed to be significantly lower in the IgM or IgG non-responder group compared to the IgM or IgG responder group (3.6 ± 3.1 vs. 6.3 ± 4.2; p-value = 0.021). The patients with IgM antibody response had a significantly lower CD20+ lymphocytes (11% versus 15% in the groups without IgM antibody response, p-value = 0.031), The percentages of NK cells and CD4+ T cells significantly increased in the patients with IgG antibody response compared to those without IgG antibody response (13% versus 10%, p-value = 0.028, and 41.5% versus 34%; p-value = 0.03, respectively). Moreover, the patients who produced IgM or IgG antibody had significantly higher percentages of total T lymphocytes (64% versus 54%; p-value = 0.017), CD4+ T cells (41% versus 34%; p-value = 0.038), and NK cells (13% versus 9%, p-value = 0.023) compared to the group with no serological response. No significant difference was observed in the percentage of other lymphocyte subsets, including CD8+ T cells, Treg cells, and CD19+ B cells. Conclusion: Our results suggest that the total T cells, CD4+ T cells, and NK cells percentages are linked to serological response. Moreover, our findings suggested that neutrophil absolute counts and neutrophil-to-lymphocyte ratio may be valuable predictors of IgM or IgG antibody response. © 2021, The Author(s).
Other Related Docs
13. Serological Tests for Covid-19: Potential Opportunities, Cell Biology International (2021)
17. Covid-19: A Trigger of Autoimmune Diseases, Cell Biology International (2023)
21. Immune Profiling of Sars-Cov-2; What We Know and What We Don’T Know, Iranian Journal of Allergy# Asthma and Immunology (2023)
27. Dynamic Changes of Lymphocyte Subsets in the Course of Covid-19, International Archives of Allergy and Immunology (2021)
28. A Review on Currently Available Potential Therapeutic Options for Covid-19, International Journal of General Medicine (2020)
33. Immune-Based Therapeutic Approaches in Covid-19, Biomedicine and Pharmacotherapy (2022)
37. Immunosenescence and Inflamm-Ageing in Covid-19, Ageing Research Reviews (2023)
38. Immune-Based Therapy for Covid-19, Advances in Experimental Medicine and Biology (2021)
40. Advances in Immunotherapy for Covid-19: A Comprehensive Review, International Immunopharmacology (2021)
45. Immunotherapy for Sars-Cov-2: Potential Opportunities, Expert Opinion on Biological Therapy (2020)